Aurobindo Pharma gets USFDA OAI status for API facility in Hyderabad

Published On 2021-11-12 09:03 GMT   |   Update On 2021-11-12 10:37 GMT

Hyderabad: Drugmaker, Aurobindo Pharma, has recently announced that the company has received Official Action Indicated (OAI) status from United States Food and Drug Administration (USFDA) for the inspection conducted at its Unit I (API) manufacturing facility in Hyderabad, India.The inspection was conducted between August 2 to August 12, 2021."The Company has received a communication from...

Login or Register to read the full article

Hyderabad: Drugmaker, Aurobindo Pharma, has recently announced that the company has received Official Action Indicated (OAI) status from United States Food and Drug Administration (USFDA) for the inspection conducted at its Unit I (API) manufacturing facility in Hyderabad, India.

The inspection was conducted between August 2 to August 12, 2021.

"The Company has received a communication from the USFDA classifying the inspection conducted at its Unit I (API) manufacturing facility in Hyderabad, India between August 2 to August 12, 2021 as Official Action Indicated (OAI), keeping the status unchanged,"  the company said in a BSE filing.

The Company believes that this inspection classification will not impact the continuing commercial supplies to the US market from this facility.

"The Company will be engaging with the regulator and is fully committed in resolving the status of this facility at the earliest," Aurobindo added.

Read also: Aurobindo Pharma, MSN seek CDSCO panel nod to cease Molnupiravir trial on moderate COVID patients

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.

The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.

Read also: Aurobindo Pharma, Glenmark recall mutliple products in US


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News